Colorectal cancer remains one of the deadliest and most therapeutically challenging cancers globally. One of the primary obstacles in treating this malignancy stems from the tumor’s intrinsic heterogeneity: the varied cellular compositions and molecular profiles observed across different tumor regions. Traditional molecular techniques such as bulk sequencing aggregate signals from mixed cellular populations, obscuring the spatial context and thereby limiting insight into localized microenvironment interactions that govern tumor progression and drug resistance.

The research team, based at Union Hospital and Tongji Medical College, Huazhong University of Science and Technology, recognized the urgent need to preserve spatial context while interrogating molecular features. To this end, they engineered the DVSTP platform to harmonize three key modalities—high-resolution histopathology images stained with hematoxylin and eosin (H&E), spatially-resolved transcriptomic profiles, and high-dimensional spatial proteomic data acquired via mass spectrometry. This integrative method fosters a multi-omics perspective where morphological, transcriptomic, and proteomic attributes converge.

Initially, the team curated a large cohort of 123 colorectal cancer specimens to develop a convolutional neural network capable of discerning diverse cell types—malignant epithelial cells, immune infiltrates, and stromal constituents—based solely on H&E histology images. Impressively, the model achieved a classification accuracy of 94%, highlighting the rich, underexploited molecular information embedded within traditional pathology slides. This discovery underscores the untapped potential of computational pathology enhanced by artificial intelligence.

The true novelty of DVSTP arose when the researchers turned their attention to spatial heterogeneity within individual tumors. Utilizing serial sections from two anatomically distinct sites of a stage II colorectal carcinoma, they processed an extensive series of 380 tissue slices. The resulting datasets enabled meticulous three-dimensional reconstruction of tumor architecture, unveiling spatial cell organization and intercellular interactions with unprecedented resolution. This approach bridges a critical gap by revealing how cellular neighborhoods correlate with distinct molecular programs.

A comparative analysis between spatial transcriptomics and proteomics data revealed a surprisingly modest concordance between mRNA abundance and protein levels across tumor regions. With an average Spearman correlation coefficient of 0.37, these findings highlight the complex post-transcriptional regulatory mechanisms that modulate protein expression. This disparity affirms the necessity of incorporating direct proteomic measurements in spatial studies to authentically capture functional cellular states rather than relying solely on transcriptomic surrogates.

The proteomics component of the DVSTP analysis identified 2,805 proteins exhibiting diverse expression patterns throughout tumor territories. Clustering based on protein signatures stratified the tumor into four molecularly distinct subtypes, each defined by unique compositions of signaling pathways and biological processes. This granular classification offers a refined understanding of tumor biology that may inform stratified therapeutic interventions targeting specific tumor niches.

Strikingly, the study demonstrated that computational evaluation of routine pathological images alone could robustly predict molecular profiles. The deep learning model achieved an area under the curve (AUC) of 0.718 for predicting spatial protein expression patterns from H&E images, improving to 0.755 when transcriptomic data were integrated. These findings eloquently attest to the latent molecular insights encoded within tissue morphology, foreshadowing a future where diagnostic imaging and AI coalesce to guide clinical decision-making.

Among the diverse protein markers characterized, Serine/Arginine-Rich Splicing Factor 6 (SRSF6) emerged as a pivotal molecule delineating spatial heterogeneity and immunological landscapes within colorectal tumors. Regions exhibiting elevated SRSF6 expression correlated with pronounced exclusion of CD4⁺ and CD8⁺ T cells, highlighting an immunosuppressive microenvironment that likely promotes tumor immune evasion. This association positions SRSF6 as a central architect of the tumor-immune interface.

Mechanistic validation through in vitro and in vivo experiments reinforced the role of SRSF6 in driving colorectal cancer progression. Overexpression of Srsf6 in cancer cell lines and mouse models enhanced migratory capacity and tumor growth while concomitantly diminishing T cell infiltration. Conversely, genetic knockdown of Srsf6 reversed these phenotypes, illustrating its functional contribution to both tumor aggressiveness and immune modulation. Clinically, elevated SRSF6 expression portended poorer overall survival, underscoring its prognostic significance.

The researchers emphasize that although emerging spatial omics platforms are rapidly evolving, technological constraints regarding resolution and cost have thus far limited widespread clinical adoption. DVSTP addresses these challenges by computationally deconvoluting spatial data to enhance effective resolution and leveraging ubiquitously accessible H&E-stained slides for molecular inference. This pragmatic approach democratizes access to spatial multi-omics and accelerates translational research.

Moreover, DVSTP’s capacity for reconstructing whole tumors in three dimensions transcends conventional two-dimensional histological analysis, enabling revelation of spatial infiltration patterns and molecular gradients invisible at planar sections. This comprehensive spatial insight holds promise for clinical applications ranging from pinpointing aggressive tumor regions prone to metastasis, to tailoring immunotherapeutic strategies based on localized immune landscapes, thus heralding a new era of precision oncology.

In sum, the Deep Visual Spatial Transcriptomics and Proteomics strategy presents a transformative platform to unravel the complex biological and spatial heterogeneity inherent in colorectal cancer. By fusing advanced computational tools with multi-omics data and traditional pathology, DVSTP paves the way for more nuanced tumor characterization, improved prognostic stratification, and ultimately, more effective and personalized cancer treatment paradigms.

Subject of Research: Integrative deep learning and spatial multi-omics analysis of intra-tumor heterogeneity in colorectal cancer

Article Title: Deep Visual Spatial Transcriptomics and Proteomics strategy reveals intra-tumor heterogeneity

News Publication Date: Not provided

Web References: http://dx.doi.org/10.1016/j.scib.2026.04.047

References: Not provided

Image Credits: ©Science Bulletin

Keywords: colorectal cancer, intra-tumor heterogeneity, spatial transcriptomics, spatial proteomics, deep learning, computational pathology, tumor microenvironment, SRSF6, immune exclusion, 3D tumor reconstruction, precision oncology

The study commenced with a thorough exploration of gene expression levels using multiple public repositories such as the Cancer Cell Line Encyclopedia (CCLE), Human Protein Atlas (HPA), European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI), and the Gene Expression Profiling Interactive Analysis version 2 (GEPIA2). The findings demonstrated that MEF2A, MEF2C, and MEF2D are notably overexpressed in pancreatic cancer tissues compared to their normal counterparts. Conversely, MEF2B did not display significant differential expression, highlighting the distinct roles that individual MEF2 family proteins might play in pancreatic carcinogenesis.

Protein-level validations corroborated the elevated presence of MEF2A, MEF2C, and MEF2D in tumor samples. Such concordance between mRNA and protein expression levels fortifies the hypothesis that these transcription factors could serve as credible biomarkers for the disease. The investigation then delved into the epigenetic regulation of these genes, particularly focusing on DNA methylation patterns analyzed via the DiseaseMeth database and verified by MEXPRESS. The researchers discovered a consistent negative correlation between the expression of MEF2A, MEF2C, and MEF2D and their respective methylation status at diverse genomic loci, suggesting epigenetic demethylation as a potential mechanism driving their upregulation in PAAD.

Prognostic implications were rigorously assessed using Kaplan–Meier Plotter and GEPIA2 survival analyses. Elevated MEF2A expression was robustly associated with poorer overall survival (OS) and relapse-free survival (RFS), indicating its potential utility as a prognostic biomarker. Similarly, high levels of MEF2C correlated with worse RFS, implicating its role in tumor recurrence and progression. While MEF2D’s impact on clinical outcomes was less definitive, its biological significance remains compelling given its overexpression and mutation profile.

Addressing the genetic landscape, the study employed the cBioPortal database to probe mutational events within these genes. MEF2A was identified predominantly with a truncating mutation, notably the G27Wfs*8 frameshift mutation located within the serum response factor–transcription factor (SRF-TF) domain, which could disrupt its transcriptional functionality. In contrast, MEF2C and MEF2D harbored missense mutations, potentially altering their protein structure and activity. These mutations may contribute to aberrant transcriptional regulation, fostering oncogenic processes within pancreatic cells.

The tumor microenvironment’s immune context was another focal point investigated via the Tumor Immune Estimation Resource (TIMER) database. Remarkably, the expression of MEF2A, MEF2C, and MEF2D showed significant positive correlations with the infiltration of five key immune cell types: CD8+ T cells, B cells, neutrophils, macrophages, and dendritic cells. The association was particularly pronounced for CD8+ cytotoxic T lymphocytes and macrophages, immune populations that are pivotal in orchestrating anti-tumoral responses as well as tumor-promoting inflammation. These relationships underscore the dual role MEF2 factors may play in modulating immune surveillance and evasion mechanisms within the pancreatic tumor milieu.

Functional enrichment analyses using Metascape, STRING, and Cytoscape tools further illuminated the biological pathways linked to MEF2 overexpression. Among numerous pathways identified, several stood out due to their involvement in PAAD pathophysiology. For instance, the cGMP-PKG signaling pathway (hsa04022) impacts cellular proliferation and apoptosis, while the NF-kappa B signaling pathway (hsa04064) is intricately involved in inflammatory and immune responses that facilitate tumor progression. Similarly, pathways associated with infectious diseases, including Leishmania infection (hsa05140) and toxoplasmosis (hsa05145), were unexpectedly connected, perhaps reflecting shared immunological or inflammatory signaling networks. The Apelin signaling pathway (hsa04371) too emerged as relevant, given its known roles in angiogenesis and tumor growth dynamics.

These mechanistic insights not only advance our understanding of how MEF2 family members contribute to pancreatic tumor development but also highlight their potential as targets for therapeutic intervention. The overexpression and mutation of MEF2A, MEF2C, and MEF2D appear to influence tumor behavior through transcriptional deregulation, immune cell interaction, and engagement of oncogenic signaling cascades. Such multifaceted roles make them attractive candidates for biomarker development and personalized medicine approaches.

Importantly, the data presented suggest that MEF2A, in particular, holds promise as a prognostic biomarker due to its association with poor survival outcomes and significant genetic alterations. MEF2C’s linkage to relapse underscores its potential as an oncogene that might be exploited for early detection of disease recurrence or as a therapeutic target. MEF2D, while less definitively tied to prognosis, still shows compelling biological relevance that warrants further investigation. Collectively, these transcription factors might form a triad of molecular indicators capable of informing diagnosis, prognostication, and treatment strategies.

Given the lethality of pancreatic cancer and the urgent need for novel molecular tools to combat it, these findings could revolutionize current clinical paradigms. The integration of MEF2 expression profiles and mutation status into routine diagnostic workflows might enable more precise stratification of patients, guiding therapeutic decisions and improving survival rates. Additionally, therapeutic agents aimed at modulating MEF2 activity or their downstream signaling pathways may emerge from this foundational work, potentially yielding new options for refractory pancreatic cancer cases.

The study exemplifies the power of leveraging multi-omics data and bioinformatics resources to unravel complex oncogenic networks. By correlating gene expression, epigenetic modulation, mutational landscapes, immune infiltration, and pathway analyses, researchers present a holistic view of the MEF2 family’s involvement in pancreatic cancer. This integrative approach sets a new standard for biomarker research and opens avenues for deeper mechanistic studies.

As pancreatic cancer continues to pose formidable challenges to clinicians and patients alike, innovative research such as this provides hope for breakthroughs in diagnosis and therapy. The identification of MEF2A, MEF2C, and MEF2D as key molecular players adds critical pieces to the pancreatic cancer puzzle and underscores the necessity of continued investigation into transcription factor networks and tumor-immune interactions. Future studies may build on these findings to translate them into clinical tools that save lives and improve patient quality of life.

In conclusion, the compelling evidence amassed points to MEF2A as a robust prognostic marker for pancreatic cancer, with MEF2C serving a potential oncogenic role and MEF2D holding significant biological implications. The interplay between their overexpression, genetic mutations, and immunological associations underscores their multifaceted impact on tumor biology. These insights not only deepen our molecular understanding of pancreatic cancer but also pave the way for novel biomarker-driven clinical interventions, fostering hope against one of the most formidable cancer types.

Subject of Research: Investigation of MEF2 family transcription factors (MEF2A, MEF2C, MEF2D) as biomarkers and functional contributors in pancreatic adenocarcinoma.

Article Title: MEF2A, MEF2C, and MEF2D as potential biomarkers of pancreatic cancer?

Article References:
Zhai, C., Ding, X., Mao, L. et al. MEF2A, MEF2C, and MEF2D as potential biomarkers of pancreatic cancer?
BMC Cancer 25, 775 (2025). https://doi.org/10.1186/s12885-025-14107-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14107-x